医用和娱乐用大麻州法律是否影响全关节置换术患者术后阿片类药物处方趋势?
该研究基于MarketScan商业和Medicare补充索赔与就诊数据库,纳入2017年5月1日至2021年9月30日期间129,132例住院全关节置换术(THA=49,718例,TKA=79,414例),采用双重差分分析比较医用或娱乐用大麻合法化州与未变化州之间围手术期阿片类药物处方趋势。结果显示医用大麻合法化对MME/天无影响(双重差分变化4.38 [95%CI -4.49至13.22]),而娱乐用大麻合法化与MME/天增加相关(双重差分变化8.83 [95%CI 0.22至17.43])。
要点
- 医用大麻合法化与围手术期阿片类药物使用变化无显著关联(双重差分变化4.38 [95%CI -4.49至13.22])。
- 娱乐用大麻合法化与围手术期MME/天增加相关(双重差分变化8.83 [95%CI 0.22至17.43])。
- 女性和TKA患者及既往无阿片类药物使用患者在娱乐用大麻合法化后阿片类药物使用增加。
核心结论
- 医用大麻合法化实施未观察到差异。
- 娱乐用大麻合法化与全关节置换术围手术期MME/天增加相关。
- 实施娱乐用大麻法律的州的外科医生应意识到患者大麻可获得性增加及其对术后疼痛和阿片类药物使用的潜在影响。
研究设计与样本
- 查询MarketScan商业和Medicare补充索赔与就诊数据库,评估2017年5月1日至2021年9月30日期间THA和TKA围手术期阿片类药物使用。
- 识别129,132例住院全关节置换术(THA=49,718例,TKA=79,414例)。
- 围手术期定义为术前30天至术后90天。
- 使用所有50个州和华盛顿特区医用和娱乐用大麻合法化生效日期,进行双重差分分析,比较合法化州与未变化州TJA患者门诊阿片类药物处方趋势。
主要发现
- 医用大麻合法化对MME/天无影响(双重差分变化4.38 [95%CI -4.49至13.22])。
- 娱乐用大麻合法化实施与MME/天增加相关(双重差分变化8.83 [95%CI 0.22至17.43])。
- 医用和娱乐用大麻法律实施均与女性围手术期阿片类药物处方增加相关。
- 娱乐用大麻合法化与TKA患者及既往无阿片类药物使用患者阿片类药物使用增加相关。
临床怎么用
- 实施娱乐用大麻法律的州的外科医生应意识到患者大麻可获得性增加及其对术后疼痛和阿片类药物使用的潜在影响。
局限性
- 证据等级为III级,治疗性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Total joint arthroplasty (TJA) is a painful procedure frequently managed with opioid medication, which puts patients at risk for chronic opioid use. Marijuana is a pain modifier and may be an effector of opioid-use reduction. Recently, many states have legalized the use of medical and recreational marijuana, and these legalization events have correlated with reductions in opioid prescriptions. This trend has not yet been demonstrated in the context of orthopaedic surgery, and there is limited evidence overall investigating the effect of marijuana on perioperative opioid use in TJA. QUESTION/PURPOSES: (1) Is legalization of medical marijuana associated with changes in perioperative opioid use in patients who have undergone TJA? (2) Is legalization of recreational marijuana associated with changes in perioperative opioid use in patients who have undergone TJA? (3) Are these changes observed in any specific subpopulations of patients who have undergone TJA? METHODS: The MarketScan Commercial and Medicare Supplemental Claims and Encounters Database was queried to assess the relative effect of marijuana legalization on perioperative opioid use in THA and TKA between May 1, 2017, and September 30, 2021, which was around and after the time that the opioid crisis was declared a public health emergency. We identified 129,132 inpatient TJA procedures (THA = 49,718, TKA = 79,414). The perioperative period was defined as 30 days before surgery and 90 days after surgery. We used the recreational and medical marijuana legalization effective dates in all 50 states and Washington, DC to conduct a difference-in-difference analysis to compare trends of outpatient opioid prescriptions among patients who underwent TJA in states with legalizations of medical or recreational marijuana with those among patients who underwent TJA in states without a change in marijuana legalization status. RESULTS: We observed no impact of medical marijuana legalization on morphine milligram equivalent (MME)/day (difference-in-difference change 4.38 [95% confidence interval (CI) -4.49 to 13.22]). However, recreational marijuana legalization implementation was associated with an increase in MME/day (difference-in-difference change 8.83 [95% CI 0.22 to 17.43]). When we looked at specific patient groups, the implementations of medical and recreational marijuana laws were both associated with increases in perioperative opioid prescriptions in women, while recreational marijuana legalization was associated with increased opioid use in patients undergoing TKA and patients without prior use of opioids. CONCLUSION: We did not identify differences with respect to medical marijuana legalization implementation. However, we found that recreational marijuana legalization was associated with an increase in perioperative MME/day for TJA. This is important because surgeons in states with the implementation of recreational marijuana law should be aware of the potential for increased marijuana availability for their patients and how this may impact their postoperative course, particularly with respect to pain and opioid utilization. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Grant A, Niu R, Michalowski A, et al. Do Medical and Recreational Marijuana State Laws Impact Trends in Postoperative Opioid Prescriptions Among Patients Who Have Undergone TJA? Clin Orthop Relat Res. 2025. PMID: 39982017. doi:10.1097/CORR.0000000000003422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。